CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more
CEL-SCI Corp (CVM) - Net Assets
Latest net assets as of December 2025: $11.14 Million USD
Based on the latest financial reports, CEL-SCI Corp (CVM) has net assets worth $11.14 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($22.89 Million) and total liabilities ($11.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.14 Million |
| % of Total Assets | 48.65% |
| Annual Growth Rate | N/A |
| 5-Year Change | -71.77% |
| 10-Year Change | N/A |
| Growth Volatility | 98993.93 |
CEL-SCI Corp - Net Assets Trend (1986–2025)
This chart illustrates how CEL-SCI Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CEL-SCI Corp (1986–2025)
The table below shows the annual net assets of CEL-SCI Corp from 1986 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $15.96 Million | +24.01% |
| 2024-09-30 | $12.87 Million | -2.63% |
| 2023-09-30 | $13.21 Million | -58.91% |
| 2022-09-30 | $32.16 Million | -43.11% |
| 2021-09-30 | $56.53 Million | +186.59% |
| 2020-09-30 | $19.73 Million | +284.26% |
| 2019-09-30 | $5.13 Million | +560344.00% |
| 2018-09-30 | $916.00 | +100.03% |
| 2017-09-30 | $-3.34 Million | -249.03% |
| 2016-09-30 | $-956.07K | +81.72% |
| 2015-09-30 | $-5.23 Million | -150.08% |
| 2014-09-30 | $10.44 Million | +55.87% |
| 2013-09-30 | $6.70 Million | -4.66% |
| 2012-09-30 | $7.03 Million | -22.60% |
| 2011-09-30 | $9.08 Million | -67.41% |
| 2010-09-30 | $27.85 Million | +215.08% |
| 2009-09-30 | $8.84 Million | -18.41% |
| 2008-09-30 | $10.84 Million | -26.14% |
| 2007-09-30 | $14.67 Million | +1676.41% |
| 2006-09-30 | $-930.60K | -144.21% |
| 2005-09-30 | $2.11 Million | -60.27% |
| 2004-09-30 | $5.30 Million | +332.44% |
| 2003-09-30 | $1.23 Million | +15.34% |
| 2002-09-30 | $1.06 Million | -73.45% |
| 2001-09-30 | $4.00 Million | -69.13% |
| 2000-09-30 | $12.96 Million | +82.56% |
| 1999-09-30 | $7.10 Million | -49.29% |
| 1998-09-30 | $14.00 Million | +141.38% |
| 1997-09-30 | $5.80 Million | -50.00% |
| 1996-09-30 | $11.60 Million | +141.67% |
| 1995-09-30 | $4.80 Million | -28.36% |
| 1994-09-30 | $6.70 Million | -38.53% |
| 1993-09-30 | $10.90 Million | -18.05% |
| 1992-09-30 | $13.30 Million | +1377.78% |
| 1991-09-30 | $900.00K | -- |
| 1990-09-30 | $0.00 | -- |
| 1989-09-30 | $0.00 | -- |
| 1988-09-30 | $-100.00K | -125.00% |
| 1987-09-30 | $400.00K | +500.00% |
| 1986-09-30 | $-100.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to CEL-SCI Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 53372291600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $80.16K | 0.50% |
| Other Components | $555.30 Million | 3479.96% |
| Total Equity | $15.96 Million | 100.00% |
CEL-SCI Corp Competitors by Market Cap
The table below lists competitors of CEL-SCI Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hiroca Holdings Ltd
TW:1338
|
$26.55 Million |
|
LTCEF
OTCGREY:LTCEF
|
$26.55 Million |
|
Boom Logistics Ltd
AU:BOL
|
$26.58 Million |
|
Airmate Cayman International Co Ltd
TW:1626
|
$26.62 Million |
|
Beam Global
NASDAQ:BEEM
|
$26.53 Million |
|
Chosun Refractories Co Ltd
KO:000480
|
$26.52 Million |
|
Hotel Property Investments Ltd
AU:HPI
|
$26.52 Million |
|
Busan Ind
KO:011390
|
$26.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CEL-SCI Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,867,083 to 15,957,085, a change of 3,090,002 (24.0%).
- Net loss of 25,411,055 reduced equity.
- Share repurchases of 28,511,100 reduced equity.
- New share issuances of 28,511,095 increased equity.
- Other factors increased equity by 28,501,062.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.41 Million | -159.25% |
| Share Repurchases | $28.51 Million | -178.67% |
| Share Issuances | $28.51 Million | +178.67% |
| Other Changes | $28.50 Million | +178.61% |
| Total Change | $- | 24.01% |
Book Value vs Market Value Analysis
This analysis compares CEL-SCI Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.91x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1986-09-30 | $-387.96 | $3.59 | x |
| 1987-09-30 | $1411.78 | $3.59 | x |
| 1988-09-30 | $-288.47 | $3.59 | x |
| 1989-09-30 | $-25909.56 | $3.59 | x |
| 1990-09-30 | $-26250.00 | $3.59 | x |
| 1991-09-30 | $2250.00 | $3.59 | x |
| 1992-09-30 | $23470.86 | $3.59 | x |
| 1993-09-30 | $20437.63 | $3.59 | x |
| 1994-09-30 | $12562.58 | $3.59 | x |
| 1995-09-30 | $273.85 | $3.59 | x |
| 1996-09-30 | $15768.80 | $3.59 | x |
| 1997-09-30 | $4627.71 | $3.59 | x |
| 1998-09-30 | $307.58 | $3.59 | x |
| 1999-09-30 | $3676.45 | $3.59 | x |
| 2000-09-30 | $5047.61 | $3.59 | x |
| 2001-09-30 | $1375.04 | $3.59 | x |
| 2002-09-30 | $277.13 | $3.59 | x |
| 2003-09-30 | $179.72 | $3.59 | x |
| 2004-09-30 | $576.49 | $3.59 | x |
| 2005-09-30 | $7.15 | $3.59 | x |
| 2006-09-30 | $-74.38 | $3.59 | x |
| 2007-09-30 | $1130.68 | $3.59 | x |
| 2008-09-30 | $694.26 | $3.59 | x |
| 2009-09-30 | $496.54 | $3.59 | x |
| 2010-09-30 | $1033.70 | $3.59 | x |
| 2011-09-30 | $326.60 | $3.59 | x |
| 2012-09-30 | $6.98 | $3.59 | x |
| 2013-09-30 | $126.98 | $3.59 | x |
| 2014-09-30 | $4.44 | $3.59 | x |
| 2015-09-30 | $-1.58 | $3.59 | x |
| 2016-09-30 | $-0.20 | $3.59 | x |
| 2017-09-30 | $-0.42 | $3.59 | x |
| 2018-09-30 | $0.00 | $3.59 | x |
| 2019-09-30 | $0.16 | $3.59 | x |
| 2020-09-30 | $16.10 | $3.59 | x |
| 2021-09-30 | $41.68 | $3.59 | x |
| 2022-09-30 | $22.36 | $3.59 | x |
| 2023-09-30 | $8.91 | $3.59 | x |
| 2024-09-30 | $6.47 | $3.59 | x |
| 2025-09-30 | $3.93 | $3.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CEL-SCI Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -159.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.76x
- Recent ROE (-159.25%) is above the historical average (-87038.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1986 | 0.00% | -2900.00% | 0.33x | 0.00x | $-2.89 Million |
| 1987 | -425.00% | -1700.00% | 0.14x | 1.75x | $-1.74 Million |
| 1988 | 0.00% | -1300.00% | 0.17x | 0.00x | $-1.29 Million |
| 1989 | 0.00% | -1100.00% | 0.20x | 0.00x | $-150.00K |
| 1990 | 0.00% | -900.00% | 0.20x | 0.00x | $150.00K |
| 1991 | -133.33% | -1200.00% | 0.06x | 1.78x | $-1.29 Million |
| 1992 | -12.78% | -425.00% | 0.03x | 1.04x | $-3.03 Million |
| 1993 | -22.02% | -240.00% | 0.09x | 1.06x | $-3.49 Million |
| 1994 | -65.67% | -4400.00% | 0.01x | 1.21x | $-5.07 Million |
| 1995 | -81.25% | -3900.00% | 0.02x | 1.33x | $-4.38 Million |
| 1996 | -54.31% | -2100.00% | 0.03x | 1.03x | $-7.46 Million |
| 1997 | -141.38% | -2050.00% | 0.06x | 1.09x | $-8.78 Million |
| 1998 | -45.71% | -6400.00% | 0.01x | 1.03x | $-7.80 Million |
| 1999 | -105.63% | -1875.00% | 0.05x | 1.07x | $-8.21 Million |
| 2000 | -65.41% | -2109.00% | 0.03x | 1.07x | $-9.77 Million |
| 2001 | -268.26% | -2853.02% | 0.08x | 1.13x | $-11.13 Million |
| 2002 | -785.40% | -2167.16% | 0.10x | 3.55x | $-8.45 Million |
| 2003 | -520.08% | -2001.70% | 0.11x | 2.38x | $-6.49 Million |
| 2004 | -79.27% | -1290.32% | 0.06x | 1.04x | $-4.73 Million |
| 2005 | -144.40% | -1126.09% | 0.09x | 1.47x | $-3.25 Million |
| 2006 | 0.00% | -6328.23% | 0.01x | 0.00x | $-7.85 Million |
| 2007 | -65.64% | -16881.40% | 0.00x | 1.41x | $-11.10 Million |
| 2008 | -71.09% | -152091.12% | 0.00x | 1.36x | $-8.79 Million |
| 2009 | -462.75% | -51078.16% | 0.00x | 5.21x | $-41.79 Million |
| 2010 | 37.64% | 6838.51% | 0.00x | 1.36x | $7.70 Million |
| 2011 | -283.21% | -2689.14% | 0.05x | 2.05x | $-26.62 Million |
| 2012 | -220.24% | -6078.83% | 0.02x | 2.29x | $-16.18 Million |
| 2013 | -136.88% | -5746927.56% | 0.00x | 1.62x | $-9.84 Million |
| 2014 | -262.04% | -10364831.65% | 0.00x | 1.84x | $-28.41 Million |
| 2015 | 0.00% | -5274.70% | 0.04x | 0.00x | $-34.15 Million |
| 2016 | 0.00% | -4022.56% | 0.02x | 0.00x | $-11.37 Million |
| 2017 | 0.00% | -20810.33% | 0.00x | 0.00x | $-14.03 Million |
| 2018 | -3475677.40% | -6680.68% | 0.02x | 32299.59x | $-31.84 Million |
| 2019 | -481.00% | -5336.04% | 0.02x | 5.38x | $-25.21 Million |
| 2020 | -163.35% | -5767.93% | 0.01x | 2.05x | $-34.20 Million |
| 2021 | -69.32% | 0.00% | 0.00x | 1.34x | $-44.84 Million |
| 2022 | -118.98% | 0.00% | 0.00x | 1.57x | $-41.48 Million |
| 2023 | -244.92% | 0.00% | 0.00x | 2.31x | $-33.69 Million |
| 2024 | -209.22% | 0.00% | 0.00x | 2.10x | $-28.21 Million |
| 2025 | -159.25% | 0.00% | 0.00x | 1.76x | $-27.01 Million |
Industry Comparison
This section compares CEL-SCI Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CEL-SCI Corp (CVM) | $11.14 Million | 0.00% | 1.06x | $26.54 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |